Entrada Therapeutics, Inc. (NASDAQ:TRDA) COO Nathan J. Dowden Sells 1,904 Shares of Stock

Entrada Therapeutics, Inc. (NASDAQ:TRDA) COO Nathan J. Dowden sold 1,904 shares of the company’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $15.07, for a total value of $28,693.28. Following the completion of the sale, the chief operating officer now owns 125,996 shares in the company, valued at approximately $1,898,759.72. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Entrada Therapeutics Trading Down 2.1 %

Shares of Entrada Therapeutics stock opened at $14.72 on Wednesday. The company has a market cap of $496.93 million, a P/E ratio of 23.37 and a beta of -0.24. The business has a 50-day moving average price of $16.03 and a two-hundred day moving average price of $14.65. Entrada Therapeutics, Inc. has a 1-year low of $10.75 and a 1-year high of $18.17.

Entrada Therapeutics (NASDAQ:TRDA) last issued its earnings results on Tuesday, August 13th. The company reported $1.55 earnings per share for the quarter, topping analysts’ consensus estimates of $0.65 by $0.90. The business had revenue of $94.69 million during the quarter, compared to the consensus estimate of $55.00 million. Entrada Therapeutics had a return on equity of 35.16% and a net margin of 43.63%. Equities research analysts forecast that Entrada Therapeutics, Inc. will post 0.68 EPS for the current fiscal year.

Institutional Investors Weigh In On Entrada Therapeutics

A number of large investors have recently bought and sold shares of TRDA. The Manufacturers Life Insurance Company raised its holdings in shares of Entrada Therapeutics by 3.9% during the second quarter. The Manufacturers Life Insurance Company now owns 57,098 shares of the company’s stock valued at $814,000 after purchasing an additional 2,146 shares during the period. Marshall Wace LLP raised its stake in Entrada Therapeutics by 27.5% during the 2nd quarter. Marshall Wace LLP now owns 65,943 shares of the company’s stock worth $940,000 after buying an additional 14,220 shares during the period. Renaissance Technologies LLC bought a new position in Entrada Therapeutics in the second quarter worth approximately $636,000. American Century Companies Inc. grew its stake in Entrada Therapeutics by 5.1% in the second quarter. American Century Companies Inc. now owns 384,973 shares of the company’s stock valued at $5,486,000 after acquiring an additional 18,625 shares during the period. Finally, Acadian Asset Management LLC increased its holdings in shares of Entrada Therapeutics by 135.1% during the second quarter. Acadian Asset Management LLC now owns 13,367 shares of the company’s stock valued at $190,000 after acquiring an additional 7,682 shares in the last quarter. 86.39% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts recently commented on the company. Oppenheimer reiterated an “outperform” rating and issued a $25.00 target price on shares of Entrada Therapeutics in a report on Monday, August 26th. HC Wainwright reaffirmed a “buy” rating and issued a $18.00 price objective on shares of Entrada Therapeutics in a research note on Wednesday, August 14th.

Entrada Therapeutics Company Profile

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.